Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma

Neuro-Oncology

Volumn 17, Issue 2, 2015, Pages 266-273

  Penas Prado, Marta ^a   Hess, Kenneth R ^a   Fisch, Michael J ^a   Lagrone, Lore W ^a   Groves, Morris D ^a   Levin, Victor A ^a,b   De Groot, John F ^a   Puduvalli, Vinay K ^c   Colman, Howard ^d   Volas Redd, Gena ^e   Giglio, Pierre ^f   Conrad, Charles A ^a   Salacz, Michael E ^g   Floyd, Justin D ^h   Loghin, Monica E ^a   Hsu, Sigmund H ⁱ   Gonzalez, Javier ^j   Chang, Eric L ^k   Woo, Shiao Y ^l   Mahajan, Anita ^a   Aldape, Kenneth D ^a   Yung, W K Alfred ^a   Gilbert, Mark R ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e Georgia Cancer Specialists   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^h St Francis Medical Center Cape Girardeau   (United States)

ⁱ UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^j WEST VIRGINIA UNIVERSITY   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

more..

Author keywords

celecoxib; Factorial design; glioblastoma; isotretinoin; temozolomide; thalidomide

Indexed keywords

CELECOXIB; ISOTRETINOIN; TEMOZOLOMIDE; THALIDOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG COMBINATION; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CHEMORADIOTHERAPY; CHILD; CONTROLLED STUDY; DOSE DENSIFICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA MULTIFORME; EXTERNAL BEAM RADIOTHERAPY; FACTORIAL DESIGN; FEMALE; GLIOBLASTOMA; HUMAN; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELECOXIB; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; GLIOBLASTOMA; HUMANS; ISOTRETINOIN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PYRAZOLES; SULFONAMIDES; THALIDOMIDE; YOUNG ADULT;

EID: 84924965220     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou155     Document Type: Article

References (33)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Chang SM, Butowski NA, Sneed PK, et al. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. Neurosurg Focus. 2006;20(4):E4.
3. Chowdhary S, Chamberlain M. Bevacizumab for the treatment of glioblastoma. Expert Rev Neurother. 2013;13(8):937-949.
4. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
5. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Ann Rev Pathol. 2014;9:1-25.
6. Brandsma D, van den Bent MJ. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol. 2007;19(6): 598-605.
7. Penas-Prado M, Gilbert MR. Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther. 2007;7(5):641-661.
8. Bozic I, Reiter JG, Allen B, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife. 2013;2:e00747.
9. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.
10. Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med. 2011;364(11):985-987.
11. Montgomery AA, Peters TJ, Little P. Design, analysis and presentation of factorial randomised controlled trials. BMC Med Res Methodol. 2003;3:26.
12. Short SC, Traish D, Dowe A, et al. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol. 2001; 51(1):41-45.
13. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18(4):708-715.
14. Jaeckle KA, Hess KR, Yung WK, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003;21(12): 2305-2311.
15. Yung WK, Lotan R, Lee P, et al. Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells. Cancer Res. 1989;49(4):1014-1019.
16. Yung WK, Kyritsis AP, Gleason MJ, et al. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res. 1996;2(12):1931-1935.
17. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61(11):4375-4381.
18. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000;60(17):4926-4931.
19. Kang SG, Kim JS, Park K, et al. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep. 2006;15(1):7-13.
20. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88(7):1004-1011.
21. Wick W, Steinbach JP, Kuker WM, et al. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004;62(11):2113-2115.
22. Gilbert MR, Gonzalez J, Hunter K, et al. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol. 2010;12(11):1167-1172.
23. Macdonald DR, Cascino TL, Schold SC Jr., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
24. Taal W, Segers-van Rijn JM, Kros JM, et al. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol. 2012;108(1):195-200.
25. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009;11(1): 69-79.
26. Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28(12):2051-2057.
27. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091.
28. Butowski N, Prados MD, Lamborn KR, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys. 2005;61(5):1454-1459.
29. See SJ, Levin VA, Yung WK, et al. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol. 2004;6(3):253-258.
30. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26(13):2192-2197.
31. Kruser TJ, Mehta MP, Robins HI. Pseudoprogression after glioma therapy: a comprehensive review. Expert Rev Neurother. 2013; 13(4):389-403.
32. McAlister FA, Straus SE, Sackett DL, et al. Analysis and reporting of factorial trials: a systematic review. JAMA. 2003;289(19): 2545-2553.
33. Green S, Liu PY, O'Sullivan J. Factorial design considerations. J Clin Oncol. 2002;20(16):3424-3430.